Studies have confirmed the close correlation of echocardiographically estim
ated pulmonary arterial pressure with invasive measurements in patients wit
h chronic obstructive pulmonary disease (COPD), but there are few data on u
tility of echocardiographic measurement in assessing pulmonary arterial hyp
ertension (PH) in COPD and correlation with pulmonary function tests.
Presence or absence of tricuspid regurgitation (TR) was determined by Doppl
er echocardiography in 73 consecutive COPD patients attending a hospital ou
tpatient clinic. Transtricuspid pressure gradient (TTPG) was calculated. PH
was defined as TTPG greater than or equal to 30 mmHg. Patients also underw
ent spirometry, forced expiratory volume in one second (FEV1), single breat
h gas transfer (carbon monoxide transfer coefficient; (Kco) and carbon mono
xide diffusing capacity of the lung; DL,CO) and arterial blood gas measurem
ent.
Measurable TR was observed in 56/73 patients (77%). There were no differenc
es between the group in which TR was observed compared to that in which it
was absent, with regard to age, smoking history nor pulmonary function vari
ables. PH was seen in 31/56 cases (55%), with good reproducibility. There w
ere statistically significant correlations of TTPG with FEV1 (r = -0.26, p
= 0.05), Kco (r = -0.31, p = 0.04) and D-L,CO (r = -0.42, p = 0.006) expres
sed as % pred. Stepwise regression analysis showed that age and Kco combine
d provide a multivariate model for prediction of TTPG.
It is concluded the presence and degree of pulmonary arterial hypertension
is readily and reliably determined by echocardiography in the majority of c
hronic obstructive pulmonary disease patients. Pulmonary arterial hypertens
ion is common in severe chronic obstructive pulmonary disease and transtric
uspid pressure gradient correlates with spirometry and indices of gas trans
fer, similar to previous invasive studies. In view of the adverse effects o
f pulmonary arterial hypertension on morbidity and mortality routine echoca
rdiography in patients with severe chronic obstructive pulmonary disease ma
y be warranted.